Guardian Pharmacy Services, Inc. Q1 FY2026 earnings call

Fred Burke mentioned that Guardian delivered solid results in the first quarter, with a 2% revenue increase despite a 60% decline in pricing across branded drug mix impacted by IRA. They proactively took actions to offset IRA's approximately $10 million headwind, achieving double-digit gross profit growth. The IRA introduced changes in operational mechanics, payment timing, and cash flow, but the team navigated them effectively. Also, the IRA created a one-time working capital reset, which Guardian managed. David Morris discussed underlying drivers like total residents up 10%, script volumes up 10%, revenue from organic growth, acquisitions, and plan optimization. SG&A included $3.2 million legal expense related to reimbursement, and a $8.5 million cash payment will be recognized in Q2. Acquisitions' profitability dampened margins by 80 basis points. Balance sheet had $65 million cash, flat with year end. Revenue guidance remains $1.4 to $1.42 billion, adjusted EBITDA guidance updated to $123 million to $127 million.

Revenue for the quarter was $336.6 million, up 2% year over year. Gross profit was $76 million, up 19% year over year. Total residents increased 10% year over year to approximately 207,000 at the quarter end, with assisted living residents representing roughly 70% of the mix. Script volumes were also strong, increasing 10% year over year. Absent the government mandated price declines from the IRA, revenues would have been up low double digits year over year. Gross profit, absent the $3 million benefit, grew 14%. Acquisitions completed over the past two years are collectively contributing modest profitability in the quarter, but remaining well below the consolidated margin profile, dampening margins by approximately 80 basis points.

Revenue guidance remains at $1.4 to $1.42 billion. Adjusted EBITDA guidance updated to $123 million to $127 million, up from $120 million to $124 million, reflecting $3 million discrete benefits recognized in the quarter. Capital allocation priorities remain with acquisitions and greenfield investments. Confident in underlying growth drivers and IRA impact visibility.

Potential continued volatility in fuel prices, which could be a headwind of up to a few million dollars annually if prices remain elevated. Labor costs likely to trend modestly higher over remainder of year due to scaling and organizational infrastructure investment. Uncertainty around near-term legislative relief for IRA's unintended consequences.

Q: Brian Tanquilu asked about capital allocation between M&A and other priorities, Fred Burke responded about continuing steady pace with robust M&A pipeline.

Q: John Ransom asked about legal fees and relationship with PBMs, Fred Burke discussed positive and constructive discussions with payors and progress on value-based reimbursement.

Q: Alan Lutz asked about competitive landscape and impact on prospects, David Morris said pipeline remains robust and early into IRA process.

Q: Grayson McAllister asked about branded vs generic and M&A pipeline, Fred Burke and David Morris discussed ongoing efforts and large opportunity in market.

Q: Raj Kumar asked about M&A-related margin drag and organic growth, David Morris and Fred Burke responded about margin trend and ongoing initiatives.